Home » J&J $81 Million Pact Settles Off-Label Topamax Promotion
J&J $81 Million Pact Settles Off-Label Topamax Promotion
April 30, 2010
Johnson & Johnson (J&J) subsidiary Ortho-McNeil-Janssen Pharmaceuticals (OMJ) has agreed to pay $81.5 million plus interest and enter into a corporate
integrity agreement to resolve illegal promotion allegations for epilepsy drug Topamax.